CN114945573A - 髓过氧化物酶抑制剂的前药 - Google Patents

髓过氧化物酶抑制剂的前药 Download PDF

Info

Publication number
CN114945573A
CN114945573A CN202080070666.8A CN202080070666A CN114945573A CN 114945573 A CN114945573 A CN 114945573A CN 202080070666 A CN202080070666 A CN 202080070666A CN 114945573 A CN114945573 A CN 114945573A
Authority
CN
China
Prior art keywords
substituted
compound
unsubstituted
formula
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080070666.8A
Other languages
English (en)
Chinese (zh)
Inventor
G·M·杜博奇克
J·T·伦德奎斯特四世
M·A·麦克怀特
J·C·佩莱蒂埃
A·B·赖茨
E·斯特罗贝尔
张岩
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baiaohaifen Therapeutics Co ltd
Original Assignee
Baiaohaifen Therapeutics Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baiaohaifen Therapeutics Co ltd filed Critical Baiaohaifen Therapeutics Co ltd
Publication of CN114945573A publication Critical patent/CN114945573A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D515/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6509—Six-membered rings
    • C07F9/6512—Six-membered rings having the nitrogen atoms in positions 1 and 3
    • C07F9/65128—Six-membered rings having the nitrogen atoms in positions 1 and 3 condensed with carbocyclic rings or carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
CN202080070666.8A 2019-10-10 2020-10-09 髓过氧化物酶抑制剂的前药 Pending CN114945573A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962913417P 2019-10-10 2019-10-10
US62/913,417 2019-10-10
PCT/US2020/054896 WO2021072140A1 (en) 2019-10-10 2020-10-09 Prodrugs of myeloperoxidase inhibitors

Publications (1)

Publication Number Publication Date
CN114945573A true CN114945573A (zh) 2022-08-26

Family

ID=75438074

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080070666.8A Pending CN114945573A (zh) 2019-10-10 2020-10-09 髓过氧化物酶抑制剂的前药

Country Status (11)

Country Link
US (1) US20240067651A1 (https=)
EP (1) EP4041735A4 (https=)
JP (1) JP2022552834A (https=)
KR (1) KR20220080133A (https=)
CN (1) CN114945573A (https=)
AU (1) AU2020363903A1 (https=)
BR (1) BR112022006381A2 (https=)
CA (1) CA3157260A1 (https=)
IL (1) IL291891A (https=)
MX (1) MX2022004203A (https=)
WO (1) WO2021072140A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021178734A1 (en) * 2020-03-05 2021-09-10 Biohaven Therapeutics Ltd. Method of treating amyotrophic lateral sclerosis with myeloperoxidase inhibitor
CN115403584B (zh) * 2021-05-26 2024-04-02 长春金赛药业有限责任公司 2-硫代-2,3-二氢嘧啶-4-酮衍生物、药物组合物及其制备方法和应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5453426A (en) * 1989-04-19 1995-09-26 The United States Of America As Represented By The Department Of Health And Human Services Sulfur-containing xanthine derivatives as adenosine antagonists
WO2007069924A1 (en) * 2005-12-15 2007-06-21 Industrial Research Limited Deazapurine analogs of 4'-aza-l-nucleosides
US20090325986A1 (en) * 2005-12-15 2009-12-31 Richard Hubert Furneaux Deazapurine Analogs of 1'-Aza-L-Nucleosides
CN101873857A (zh) * 2007-08-23 2010-10-27 阿斯利康(瑞典)有限公司 用于治疗亨廷顿舞蹈病和多系统萎缩的mpo抑制剂
US20160039831A1 (en) * 2014-08-11 2016-02-11 Hydra Biosciences, Inc. PYRROLO[3,2-d]PYRIMIDINE-2,4(3H,5H)-DIONE DERIVATIVES

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY140748A (en) * 2004-12-06 2010-01-15 Astrazeneca Ab Novel pyrrolo [3,2-d] pyrimidin-4-one derivatives and their use in therapy
ES2691671T3 (es) * 2010-06-24 2018-11-28 Alkermes Pharma Ireland Limited Profármacos de compuestos NH-acídicos: derivados de éster, carbonato, carbamato y fosfonato
WO2016140879A1 (en) * 2015-03-03 2016-09-09 Biohaven Pharmaceutical Holding Company Ltd. Riluzole prodrugs and their use
AU2018304508B2 (en) * 2017-07-17 2021-06-10 Astrazeneca Ab MPO inhibitors for use in medicine

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5453426A (en) * 1989-04-19 1995-09-26 The United States Of America As Represented By The Department Of Health And Human Services Sulfur-containing xanthine derivatives as adenosine antagonists
WO2007069924A1 (en) * 2005-12-15 2007-06-21 Industrial Research Limited Deazapurine analogs of 4'-aza-l-nucleosides
US20090325986A1 (en) * 2005-12-15 2009-12-31 Richard Hubert Furneaux Deazapurine Analogs of 1'-Aza-L-Nucleosides
CN101873857A (zh) * 2007-08-23 2010-10-27 阿斯利康(瑞典)有限公司 用于治疗亨廷顿舞蹈病和多系统萎缩的mpo抑制剂
US20160039831A1 (en) * 2014-08-11 2016-02-11 Hydra Biosciences, Inc. PYRROLO[3,2-d]PYRIMIDINE-2,4(3H,5H)-DIONE DERIVATIVES

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
AURELIJA JUCAITE等: "Effect of the myeloperoxidase inhibitor AZD3241 on microglia: a PET study in Parkinson\'s disease", BRAIN, vol. 138, no. 9, pages 2687 - 2700, XP055816969, DOI: 10.1093/brain/awv184 *

Also Published As

Publication number Publication date
WO2021072140A1 (en) 2021-04-15
IL291891A (en) 2022-06-01
KR20220080133A (ko) 2022-06-14
AU2020363903A1 (en) 2022-03-24
BR112022006381A2 (pt) 2022-06-28
MX2022004203A (es) 2022-07-04
US20240067651A1 (en) 2024-02-29
JP2022552834A (ja) 2022-12-20
EP4041735A4 (en) 2023-11-22
CA3157260A1 (en) 2021-04-15
EP4041735A1 (en) 2022-08-17

Similar Documents

Publication Publication Date Title
JP7060298B1 (ja) Ｍｇａｔ２阻害活性を有する縮合環誘導体
US10442782B2 (en) Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
WO2021078301A1 (zh) 蛋白降解剂及其在疾病治疗中的应用
WO2018157856A1 (zh) 酰胺类衍生物抑制剂及其制备方法和应用
WO2023284703A1 (zh) 基于布鲁顿酪氨酸激酶配体设计的蛋白降解化合物及其应用
JP2020111571A (ja) Ｍｇａｔ２阻害活性を有する縮合環誘導体を含有する医薬組成物
CN114945573A (zh) 髓过氧化物酶抑制剂的前药
US9675584B2 (en) Substituted indoles for the inhibition of PASK
CN106458987A (zh) 用于治疗疾病诸如糖尿病的吡咯烷gpr40调节剂
CN114341128A (zh) 双功能蛋白降解靶向嵌合体类化合物及其制备方法和医药用途
EP2578586A1 (en) HEXAHYDROPYRROLO[3,4-b]PYRROLE DERIVATIVES, PREPARATION METHODS AND PHARMACEUTICAL USES THEREOF
CN115745963B (zh) 基于nampt靶蛋白的蛋白降解化合物及其应用
EP4644382A1 (en) Compound based on sulfur/oxygen substituted glutarimide-based isoindolinone skeleton and use thereof
CN113087724B (zh) 异噻唑并嘧啶酮类化合物，包含其的药物组合物及其用途
US20260116923A1 (en) Cyclic peptide il-1beta trap for the treatment of atherosclerosis and inflammatory disorders
CN111808105A (zh) 含有并环基团的嘧啶酮并吡唑类化合物、其制备方法及用途
HK40059861B (zh) 具有mgat-2抑制活性的稠合环衍生物
KR20250147900A (ko) 신규 티오펜 유도체 및 이의 용도
WO2024220874A2 (en) Otub1 small-molecule binders and otub1-recruiting deubiquitinase-targeting chimeras (dubtacs)
WO2026052129A1 (zh) 多环杂芳烃类glp-1受体激动剂
CN118695861A (zh) 用于治疗弗里德希共济失调的化合物和方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20220826